Multiple Myeloma | Specialty

Leonie de Best on Validation of EMC92/SKY92 Signature in Myeloma

May 4th 2016

Leonie de Best, MSc2, chief operating officer, SkylineDX, discusses the HOVON-87/NMSG-18 study, which demonstrated the validation of the EMC92/SKY92 signature for elderly patients with newly diagnosed multiple myeloma.

Early Intervention With Lenalidomide Examined in Smoldering Myeloma

May 2nd 2016

In an ongoing randomized phase III trial, researchers are looking at lenalidomide (Revlimid) compared with observation in patients with asymptomatic high-risk smoldering multiple myeloma.

NEJM Data Illuminate Efficacy of Oral Ixazomib Triplet in Myeloma

April 28th 2016

Adding ixazomib (Ninlaro) to lenalidomide (Revlimid) and dexamethasone reduced the risk of disease progression or death by 26% compared with lenalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.

Jagannath Hails "Exciting" Era in Treating Myeloma

April 5th 2016

Sundar Jagannath, MD, discusses emerging agents in multiple myeloma he is most excited about, sequencing challenges, and the role for personalized medicine in the disease.

CHMP Recommends Approval of Daratumumab for Multiple Myeloma

April 4th 2016

Single-agent daratumumab (Darzalex) for the treatment of patients with relapsed/refractory multiple myeloma previously treated with a proteasome inhibitor and an immunomodulatory agent has received a positive recommendation from the Committee for Medicinal Products for Human Use.

Dr. Rajkumar on Significance of SWOG S0777 Study for Multiple Myeloma

April 4th 2016

S. Vincent Rajkumar, MD, professor of Medicine at Mayo Clinic, discusses the significance of the phase III SWOG S0777 study, which looked at bortezomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with previously untreated multiple myeloma.

NCCN Broadens Myeloma Diagnostic Criteria, Recommends Novel Agents

April 2nd 2016

The updated NCCN myeloma guideline broadens the diagnostic criteria for active disease and integrates novel therapies into the treatment paradigm.

Dr. Anderson on How the Definition of Myeloma Has Changed

April 2nd 2016

Kenneth C. Anderson, MD, Giant of Cancer Care: Myeloma, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, discusses how the definition of myeloma has changed.

Plitidepsin Improves PFS in Advanced Myeloma

April 1st 2016

Adding plitidepsin (Aplidin) to dexamethasone reduced the risk of disease progression by 35% versus dexamethasone alone in patients with relapsed/refractory multiple myeloma enrolled in the phase III ADMYRE trial.

Daratumumab Triplet Delays Progression in Multiple Myeloma

March 30th 2016

Adding daratumumab (Darzalex) to standard bortezomib (Velcade) and dexamethasone improved progression-free survival in patients with relapsed/refractory multiple myeloma enrolled in the phase III CASTOR (MMY3004) trial.

Dr. Branagan on Vaccine to Better Protect Myeloma Patients From Flu

March 29th 2016

Andrew R. Branagan, MD, postdoctoral associate in Medicine (Hematology), Yale Cancer Center, discusses the significance of a vaccine developed to better protect patients with multiple myeloma from getting the flu.

The Future of Immunotherapy in Myeloma

March 29th 2016

On the Horizon for Multiple Myeloma

March 29th 2016

Antibodies in Combination Therapy for Myeloma

March 29th 2016

Immunotherapy Patient Selection in Myeloma

March 29th 2016

Goals of Therapy in Multiple Myeloma

March 29th 2016

Practical Advice on the Treatment of Multiple Myeloma

March 29th 2016

Safety and Efficacy of Elotuzumab in Multiple Myeloma

March 29th 2016

Safety and Efficacy of Daratumumab in Multiple Myeloma

March 29th 2016

Monoclonal Antibody Therapy in Myeloma

March 29th 2016